Court Grants Preliminary OK to $125M Zymergen Securities Settlement
A federal court preliminarily approved a $125 million settlement in Zymergen investor lawsuit.
Why it matters: The settlement underscores elevated securities litigation risks in tech and biotech, crucial for in-house counsel and litigators to track.
- The $125 million settlement was preliminarily approved on June 23, 2026, by a federal court in California.
- The case alleges Zymergen misled investors about its product-development pipeline and expected revenue.
- Defendants include Zymergen's bank underwriters, executives, directors, and major early investors like SoftBank and DCVC.
- A final fairness hearing is scheduled for October 2026 to determine final approval of the settlement.
On June 23, 2026, a federal court in California gave preliminary approval to a $125 million settlement in a securities class action lawsuit against Zymergen Inc.. The suit alleges that Zymergen misrepresented key information to investors regarding its product pipeline and revenue projections, claims the company and its representatives deny but ultimately chose to settle.
The parties include Zymergen's bank underwriters, company executives, directors, and significant early investors such as SoftBank’s SB Investment Advisers (US) Inc., DCVC Management Co., and True Venture Management LLC.
The court described the settlement terms as fair and reasonable. It will hold a final fairness hearing in October 2026 to consider any objections and decide whether to give full approval.
This settlement highlights the persistent risk of securities litigation for companies in the high-growth tech and biotech sectors. Legal teams at corporations and law firms should note the importance of disclosures about product development and revenue forecasts as potential flashpoints for investor actions.
By the numbers:
- $125 million — preliminary settlement amount approved on June 23, 2026
- October 2026 — scheduled final fairness hearing for settlement approval
What's next: The court will conduct a final fairness hearing in October 2026 to decide on final approval of the settlement.